CVT To Co-Promote Solvay's Aceon In Preparation For Ranexa Launch

CVT's 150-rep sales force will be used to promote the ACE inhibitor Aceon as well as the angina therapy Ranexa, which could launch in 2006. Aceon sales growth is tied to outcomes data expected to be added to labeling in 2005, CVT says.